GU Cancers 2020 | Long OS with sipuleucel-T in mCRPC

Name: Long OS with sipuleucel-T in mCRPC
Uploaded: 2020-02-13T00:00:00.000Z
Duration: 1 min 34 s
Description: Rana McKay, MD, University of California, San Diego, CA, discusses overall survival (OS) among medicare patients recieving sipuleucel-T versus oral treatment for metastatic castrate-resistant prostate cancer (mCRPC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Rana McKay • 13 Feb 2020

GU Cancers 2020

Genitourinary Cancer Prostate Cancer Sipuleucel-T

Rana McKay, MD, University of California, San Diego, CA, discusses overall survival (OS) among medicare patients recieving sipuleucel-T versus oral treatment for metastatic castrate-resistant prostate cancer (mCRPC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.